Form 4: Lantern Pharma CSO's Stock Options Repriced Lower

Lantern Pharma's Chief Scientific Officer, Kishor G. Bhatia, had the exercise prices of his stock options significantly reduced through a re-grant.

Summary

• Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), reported changes in his beneficial ownership of derivative securities.
• Two outstanding stock options were amended to reduce their exercise prices, involving the cancellation of 'old' options and the grant of 'replacement' options.
• The first option, originally granted on June 15, 2020, for 52,200 shares with an exercise price of $15.00, was replaced with an option for 52,200 shares at a new exercise price of $5.04.
• The second option, originally granted on October 29, 2021, for 17,400 shares with an exercise price of $10.21, was replaced with an option for 17,400 shares at a new exercise price of $5.04.
• These transactions were made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Kishor G. Bhatia beneficially owns a total of 69,600 stock options, all with an exercise price of $5.04.

Sentiment

Score: 4

Explanation: The repricing of executive stock options, while beneficial for the executive, is generally viewed negatively by the market as it often signals underperformance of the stock relative to previous expectations and can be perceived as dilutive or misaligned with shareholder interests. The positive is the retention of key personnel and compliance with 10b5-1.

Positives

• The Chief Scientific Officer's stock options were repriced to a significantly lower exercise price of $5.04, making them more 'in-the-money' or closer to the money, which could increase their intrinsic value and incentive for the officer.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged and compliant approach to equity management.

Negatives

• Option repricing, especially downwards, can be viewed negatively by shareholders as it often occurs when the stock price has fallen significantly below previous grant prices, effectively resetting the strike price to a lower market value.
• This action can dilute the value of existing options and may signal a lack of confidence in the stock's ability to recover to previous highs in the short to medium term.

Risks

• Shareholder dissatisfaction due to potential dilution and the perception of management being insulated from stock price declines.
• Potential negative impact on corporate governance ratings if repricing is not justified by exceptional circumstances or performance.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the vesting and expiration dates of the options. The repricing itself implies a management belief that the stock price may not reach the old strike prices in the near term, or it serves as an incentive to retain key personnel.

Industry Context

Option repricing is a common practice in industries, particularly biotech or high-growth sectors, where stock prices can be volatile. It is often used to re-incentivize employees when stock prices have significantly declined, making existing options underwater. However, it can also be seen as a governance concern if not handled transparently and with shareholder approval.

Comparison to Industry Standards

• Option repricing is generally viewed as a controversial practice in corporate governance, often requiring strong justification to align with best practices.
• Companies like Apple (2006) and Microsoft (2000s) have faced scrutiny for repricing options, though practices vary across the industry.
• The specific exercise price of $5.04 for both options suggests a current market price around that level, making the options 'at-the-money' or 'in-the-money' at the time of repricing, which is a common goal for such actions to restore incentive value.

Corporate Governance

Related Party Transactions

• The transaction involves an executive (Kishor G. Bhatia) and the company (Lantern Pharma Inc.), which is a related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: Potential negative perception due to option repricing, which can be seen as dilutive or as insulating management from stock price declines. May question the effectiveness of previous incentive structures.
• Executive (Kishor G. Bhatia): Significantly increased incentive and potential value of his stock options due to the lower exercise price.

Next Steps

• The options will continue to vest according to their original schedules.
• The reporting person may exercise these options in the future, subject to vesting and market conditions.

Key Dates

Recommendation

The repricing of stock options for a key executive, while often viewed negatively by investors as it suggests past underperformance and can be dilutive, also serves to re-incentivize the Chief Scientific Officer. This action aims to retain critical talent and align their future compensation with the company's stock performance from a lower base. However, without additional financial or operational updates, the implications are mixed, warranting a 'hold' recommendation to observe future performance and broader company strategy.

Keywords

Lantern Pharma, LTRN, SEC Form 4, Stock Options, Option Repricing, Executive Compensation, Kishor G. Bhatia, Chief Scientific Officer, Derivative Securities, Rule 10b5-1